secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001739410-25-000100
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio sells ENPP1 JV stake to Recursion for up to $25M; cash runway to mid-2027
--------------------------------------------------------------------------------

- Upfront equity payment of $7.5M (1,457,952 Recursion shares); potential $12.5M contingent equity and $5M clinical milestone.
- Rallybio eligible for low single-digit royalties on future net sales of REV102 (ENPP1 inhibitor for HPP).
- Deal extends Rallybio's cash runway to mid-2027; company sharpens focus on RLYB116 confirmatory study topline data this year.
- REV102 was in IND-enabling studies; Recursion gains full ownership to accelerate development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000100/0001739410-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000100/rlyb-20250708.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer